论文部分内容阅读
目的:通过对胸腺肽配合化疗治疗中晚期肺癌患者的免疫状况分析,探讨出更适合于中晚期肺癌患者的治疗方法。方法:选取我院40名中晚期肺癌患者作为实例,这些患者经过检查被确诊为非小细胞肺癌,并将其随机分为两组,并进行为期2周的胸腺肽配合化疗治疗。结果:对比发现,中晚期肺癌患者在接受胸腺肽配合化疗治疗后,肺癌患者的血清前清蛋量增加,差异有统计学意义(P<0.05)。结论:胸腺肽配合化疗治疗中晚期肺癌患者能显著提高肺癌的CD4+/CD8+水平,提高人体细胞的免疫功能。同时,也患者的机体蛋白质讲解速度明显下滑,患者的生化指标向良好的方向发展,临床症状得到了明显的缓解。
OBJECTIVE: Through the analysis of the immune status of patients with advanced lung cancer treated with thymosin and chemotherapy, we found out more suitable treatment for patients with advanced lung cancer. Methods: Forty patients with advanced lung cancer in our hospital were selected as examples. After examination, these patients were diagnosed as non-small cell lung cancer. They were randomly divided into two groups and treated with thymosin combined with chemotherapy for 2 weeks. Results: The comparison found that patients with advanced lung cancer received thymosin combined with chemotherapy, lung cancer patients before serum albumin increased, the difference was statistically significant (P <0.05). Conclusion: Thymosin combined with chemotherapy in patients with advanced lung cancer can significantly increase the level of CD4 + / CD8 + in lung cancer and improve the immune function of human cells. At the same time, the patient’s body protein was significantly lower rate of interpretation, the patient’s biochemical indicators to a good direction, clinical symptoms have been significantly alleviated.